ONCODNA
7.4.2021 08:51:06 CEST | Business Wire | Press release
OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care. The two companies agreed to consolidate their core technologies to enable the production of personalized vaccines for patients who have run out of treatment options.
With the COVID-19, the field of mRNA therapeutics has been moving faster than ever before. In oncology, personalized vaccines can help fight cancer by selectively boosting the immune system. These vaccines can teach the body to recognize and eliminate tumor-specific neoantigens.
OncoDNA and myNEO will leverage their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. While OncoDNA will perform whole genome and whole transcriptome sequencing, myNEO will handle the advanced interpretation of the sequenced data and design the optimal vaccine construct for maximum clinical benefit.
The project promises to guide patients through a completely personalized journey. The eligible patients would receive tailor-made vaccines as well as personalized follow-up by monitoring circulating tumor DNA after inoculation. With its OncoFOLLOW™ liquid biopsy, OncoDNA will help monitor the patient response and the evolution of the cancer very closely using personalized next-generation sequencing method.
“OncoDNA is delighted to jump with myNEO into this ambitious project. We stand at the forefront of innovation and the challenges ahead are herculean. Together we will work towards a world where patients with a hard-to-treat disease will have the opportunity to design their personalized elixirs. It may take years before this technology becomes a reality. However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results ”, commented Jean-Pol Detiffe, Chief Strategy & Innovation Officer and Founder of OncoDNA.
“Since day 1, myNEO’s mission has been to unlock the promise of immunotherapy via deep genomic and immune profiling of tumors,” described Cedric Bogaert, co-founder and CEO of myNEO. “Currently, our technology is used by biopharma partners to design the upcoming breakthrough immuno-oncology therapies. This project takes our ambition one step further in enabling OncoDNA’s vast network of clinicians and patients to directly benefit from this deep genomic and immune profiling. As such, this project holds great potential to make individualized immunotherapies more accessible to patients.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406006220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs to Acquire U.S.-Built Drone Manufacturer Vision Aerial, Expanding Into Global Drone and Aerial Intelligence Markets4.6.2026 14:00:00 CEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a binding Letter of Intent to acquire Vision Aerial, Inc., a Montana-based manufacturer of American-built drones trusted in national security, government, energy, public safety, and critical infrastructure operations. The acquisition expands Mobix Labs into a fast-growing global market and marks the latest step in its previously announced strategy to grow through targeted, mission-critical acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604386607/en/ Built in America. Trusted Where Performance Matters. Founded in 2013, Vision Aerial designs, manufactures, and supports rugged drone systems built for the most demanding field operations. Each aircraft can carry swappable cameras and sensors—from high-resolution and heat-sensing thermal cameras to laser-based 3-D mapping and gas-leak detection—allowing one platform to support multiple mission prof
Visa and Brale Explore Private Stablecoin Settlement for Institutional Payments4.6.2026 14:00:00 CEST | Press release
Proof of concept will test how privacy-enabled blockchain infrastructure can support secure, scalable settlement for institutional payment flows Visa (NYSE: V) today announced a collaboration with Brale to explore stablecoin-based settlement using SBC, a U.S. dollar-backed stablecoin issued by Brale, on the Canton Network. The proof of concept will evaluate how privacy-enabled blockchain infrastructure can support faster, more programmable settlement while helping financial institutions and payment companies maintain control over the visibility of sensitive settlement transaction data. Visa began enabling stablecoin settlement in 2021 and continues to expand its capabilities, allowing VisaNet obligations to be settled using supported stablecoins. A central focus of this collaboration is the Canton Network’s privacy architecture. As stablecoin adoption grows, financial institutions are assessing how they can use blockchain-based settlement while meeting strict privacy and compliance req
The Open Group Publishes Industrial Advanced Nuclear™ Consortium’s Inaugural Application Scenarios Whitepaper4.6.2026 14:00:00 CEST | Press release
The Whitepaper provides a blueprint on how advanced nuclear energy can be deployed across heavy industry The Open Group, the vendor-neutral technology standards organization, today announced the publication of the Industrial Advanced Nuclear™ Consortium (IANC) Application Scenarios Whitepaper, setting out how advanced nuclear technologies can be deployed to deliver reliable, low‑carbon heat and power across heavy industry. The Whitepaper, driven by IANC, an industrial end-user-driven organization, represents a significant step forward in the role of nuclear energy in relation to energy transition. Outlining real-world use cases where Small Modular Reactors (SMRs) and Micro Modular Reactors (MMRs) could be integrated directly into industrial operations, it focuses on sectors that are amongst the most difficult to decarbonize, including: Offshore energy Refining and petrochemicals Mining Energy‑intensive manufacturing. Developed by leading industrial end users, the Whitepaper provides a
Kinaxis Unveils 2026 Customer Award Winners at Kinexions in Las Vegas4.6.2026 13:00:00 CEST | Press release
Global supply chain leaders recognized for delivering bold innovation, agility, and measurable impact Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the winners of its 2026 Customer Awards. Now in their eighth year, these awards were celebrated live at Kinexions North America, the flagship premiere global conference hosted by Kinaxis, bringing together supply chain leaders from around the world. The annual awards spotlight organizations and individuals who are redefining what’s possible in modern supply chains. The winners are driving innovation, responding with agility, and delivering real business results with the Kinaxis Maestro™ platform. The awards recognized seven leading companies including Reckitt, General Motors, Lupin, Jabil, and Cardinal Health among the full list of winners. Additionally, Praveen Vasudevan (Bio-Rad Laboratories) received the champion award for their industry contributions. “Kinexions is where the
STARTEEPO Invest Increases Stake in Xerox to More Than 6% Ahead of Q2 2026 Earnings4.6.2026 13:00:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to more than 6% of the Company’s outstanding common stock, as disclosed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. Following the transaction, STARTEEPO beneficially owns approximately 8.0 million Xerox common shares and holds options on an additional 140,000 shares. Based on publicly available ownership disclosures, STARTEEPO is now Xerox’s third-largest shareholder. “We continue to view Xerox as a high-conviction investment and one of the largest positions in our portfolio,” said Frantisek Bostl, Chairman of the Board of STARTEEPO Invest. “Our conviction has increased as we continue to analyze the Company’s publicly available disclosures, strategic initiatives, and transformation efforts.” Increasing Conviction Ahead
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom